表紙
市場調查報告書

Casimersen:藥物的考察與至2030年的市場預測

Casimersen - Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 952558
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
Casimersen:藥物的考察與至2030年的市場預測 Casimersen - Drug Insight and Market Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 80 Pages
簡介

本報告提供全面的產品概述,包括產品說明,作用機理,劑量和給藥方式,合成途徑,藥理研究(藥效學和藥代動力學)和不良反應。涵蓋了有關Casimersen的專利訊息以及到期時間,對該空間中後期出現的新療法(第三階段)進行了全面報導,並簡要概述了細節。

本報告提供DMD治療藥物Casimersen的主要7個國家(美國,德國,法國,義大利,西班牙,英國,日本)的市場相關分析,至2030年的預測調查,產品概要,SWOT分析,到核准為止的計劃,市場評估,競爭情形,新的治療方法等資訊。

目錄

第1章 產品概要

  • 適應症
  • 作用機制
  • 投藥和管理
    • 劑型和濃度
  • 合成的路徑
  • 藥理學
    • 藥效學
    • 藥物動力學
  • 有害反應
  • 產品的概述
  • Casimersen的開發計劃
  • 市售產品詳細內容
    • 美國
    • 歐洲
    • 日本
  • 專利詳細內容

第2章 SWOT分析

  • 分析師的見解

第3章 法規的里程碑

  • 核准
  • 研究開發
  • 臨床試驗資訊
  • 安全性和有效性
  • 產品開發活動

第4章 市場評估

  • 主要7個國家的市場分析
  • 美國
  • 歐洲
  • 日本
  • 主要調查結果

第5章 市場競爭情形

第6章 新治療方法

第7章 附錄

目錄
Product Code: DIDM0034

Overview:

"Casimersen - Emerging Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Casimersen in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Casimersen uses Sarepta's proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. Casimersen is designed to bind to exon 45 of dystrophin pre-mRNA, resulting in exclusion, or "skipping," of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein. In June 2020, Sarepta Therapeutics has completed the submission of the casimersen (SRP-4045) New Drug Application (NDA) for the treatment of Duchenne muscular dystrophy (DMD) in patients who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.The completion of the rolling submission includes data from the casimersen arm of the ESSENCE study (also known as study 4045-301), a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating efficacy and safety in patients amenable to skipping exons 45 and 53. An interim analysis from ESSENCE demonstrated a statistically significant increase in dystrophin production as measured by western blot* in patients who received casimersen compared to baseline and placebo. The study is ongoing and remains blinded to collect additional efficacy and safety data. If the casimersen NDA is accepted and granted accelerated approval, the completed ESSENCE study will serve as a post-marketing confirmatory study.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Casimersen.
  • The report contains historical and forecasted sales for Casimersen till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Casimersen.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Casimersen Analytical Perspective by DelveInsight

  • In-depth Casimersen Market Assessment

This report provides a detailed market assessment of Casimersen in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Casimersen Clinical Assessment

The report provides the clinical trials information of Casimersen covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Casimersen is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Casimersen dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Casimersen and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Casimersen.
  • Our in-depth analysis of the sales data of Casimersen from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Casimersen in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Casimersen are available in the market?
  • What are the common adverse reactions or side effects of Casimersen?
  • What is the product type, route of administration and mechanism of action of Casimersen?
  • What are the chemical specifications of Casimersen?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Casimersen, and what is its future?
  • What are the marketed details of Casimersen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Casimersen and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Casimersen?
  • In which countries Casimersen got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Casimersen?
  • How the safety and efficacy results determined the approval of Casimersen?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Casimersen development?
  • What are the key designations that have been granted to Casimersen?
  • What is the historical and forecasted market scenario of Casimersen?
  • How is the market trend of Casimersen is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Casimersen?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Casimersen
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options

List of Tables

  • Table 1 Casimersen, Description
  • Table 2 Casimersen, Trial Diversification
  • Table 3 Casimersen, Marketed Details United States
  • Table 4 Casimersen, Marketed Details Europe
  • Table 5 Casimersen, Marketed Details Japan
  • Table 6 Patent Details: Casimersen
  • Table 7 Casimersen, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Casimersen
  • Table 9 Casimersen, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Casimersen, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Casimersen, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Casimersen, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Casimersen, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Casimersen
  • Figure 2 Patent Details, Casimersen
  • Figure 3 Casimersen, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Casimersen, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Casimersen, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Casimersen, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Casimersen, Japan Market Size from 2017 to 2030 (in Millions USD)